Navigation Links
NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
Date:6/3/2008

tical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of the initiation of the Phase 1 clinical trial for NGX-1998; the potential expansion of addressable markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010 and its liquid formulation product candidate NGX-1998. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010 or NGX-1998, if approved, or
'/>"/>

SOURCE NeurogesX
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... MONMOUTH JUNCTION, N.J. , Aug. 27, 2014 /PRNewswire/ ... developing innovative drug delivery technologies, today announced that it ... New Jersey Business & Industry Association,s 2014 Awards ... Finalists were selected by an independent panel of judges ... member company volunteers. Award winners will be honored at ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... it stands to reason that the next beverage craze ... Force Technology announced today that formulators can use Stress ... any ingredient used in the making of a beverage, ... natural release for stress-generated energy, channeling that power into ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 WriteResult, LLC ... – has once again shown superiority when it comes ... by completing the ePRO portion of their most recent ... The Japan-based pharma chose WriteResult’s digital writing platform to ... – the first to complete drew data from a ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... to develop bioelectronic technologies, today announced that it has ... U.S. Securities and Exchange Commission relating to a proposed ... of shares to be offered and the price range ... Jefferies LLC will act as the book-running ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... LONDON, May 3, 2012 Silence Therapeutics ... company , notes that its partner, Quark Pharmaceuticals , ... with Pfizer. This amendment will enable Quark to perform a ... in a new indication, looking at visual function in patients ...
... 2, 2012 Genomic Health, Inc. (Nasdaq: ... a strategic alliance to use Next Generation Sequencing (NGS) ... clinical development of OncoMed,s  novel antibody cancer therapeutics. ... provide Genomic Health with breast, prostate, colon and lung ...
... April 30, 2012) Barrow Neurological Institute researchers Jorge Otero-Millan, ... of the Journal of Neuroscience in a ... Barrow is part of St. Joseph,s Hospital and Medical ... laboratory, explores the neural bases of illusory motion in ...
Cached Biology Technology:Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 2Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 4Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 2Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 3Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 4Barrow researchers unravel illusion 2
(Date:8/27/2014)... Gamblers are greedy bird-brains, University of Warwick research finds ... when they make risky decisions, new research has shown. ... University of Warwick,s Department of Psychology, conducted tests that ... more likely to gamble for high-value than low-value rewards. ... argue that the test results show the important role ...
(Date:8/26/2014)... a colony of harmful bacteria, biofilms make the ... in a biofilm pose a significant health risk ... treatment, and biofilm-protected bacteria account for some 80 ... are 50 to 1,000 times more resistant to ... we may have stumbled onto a magic bullet," ...
(Date:8/26/2014)... pressure from policymakers, consumers, and suppliers has prompted ... reducing the pollutants they emit from their smokestacks ... must also assess environmental performance at every step ... materials to the use and recycling of their ... the discipline known as life cycle engineering, which ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2
... grain production must double by 2050 to address rising ... Illinois suggests crop yields will suffer unless new approaches ... Improved agronomic traits responsible for the remarkable increases in ... their ceiling for some of the world,s most important ...
... Ind. - Chemical engineers at Purdue University have developed ... biomass into biofuels, and they are proposing the creation ... to produce the fuels. "What,s important is ... -- wood chips, switch grass, corn stover, rice ...
... LAFAYETTE, Ind. - A Purdue University researcher can better retrieve ... using a newly developed technique and synthetic nanopolymer. W. ... be mapped and analyzed to find ways to inhibit the ... must be fished out of a sea of thousands of ...
Cached Biology News:'Business as usual' crop development won't satisfy future demand 2'Business as usual' crop development won't satisfy future demand 3New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3New retrieval method makes studying cancer proteins easier 2
... These 1.5L PYREX trypsinizing ... homogenous tissue samples into cell ... proteins. Heavy beaded neck accepts ... enhance vigorous agitation. • Height ...
... For the efficient enrichment of functional ... or cell culture. The isolated ER ... and metabolic pathway analysis. Metabolic abnornalities ... in children, cystic fibrosis and many ...
Plasmid expressing PLAP reporter gene....
Plasmid expressing the LacZ reporter gene....
Biology Products: